Oral Dosing of GLP-1 Compounds
US-2016067184-A1 · Mar 10, 2016 · US
Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
US10086047B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10086047-B2 |
| Application number | US-201615019412-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 9, 2016 |
| Priority date | Dec 16, 2010 |
| Publication date | Oct 2, 2018 |
| Grant date | Oct 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
First claim
Opening claim text (preview).
The invention claimed is: 1. A solid pharmaceutical composition for oral administration comprising: 0.5 to 2.5 μmol N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib 8,Arg34]GLP-1(7-37) and 0.8-1.3 mmol of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, wherein the solid pharmaceutical composition has surface eroding or co-release properties, and a disintegration time of 7-15 minutes. 2. The composition according to claim 1 , wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of the sodium salt, potassium salt and calcium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 3. The composition according to claim 2 , wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC). 4. The composition according to claim 3 , wherein said composition is in the form of a tablet. 5. The composition according to claim 4 , wherein said tablet has a weight between 300-500 mg. 6. The composition according to claim 2 , wherein said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is selected from the group consisting of the potassium salt and calcium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. 7. The composition according to claim 2 , wherein said composition is in the form of a tablet. 8. The composition according to claim 7 , wherein said tablet has a weight between 300-500 mg. 9. The composition according to claim 6 , wherein said composition is in the form of a tablet. 10. The composition according to claim 9 , wherein said tablet has a weight between 300-500 mg.
Assignees
Inventors
Classifications
Antihyperlipidemics · CPC title
Drugs for disorders of the cardiovascular system · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Anorexiants; Antiobesity agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10086047B2 cover?
- The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
- Who is the assignee on this patent?
- Novo Nordisk As
- What technology area does this patent fall under?
- Primary CPC classification A61K38/26. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).